AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03348514
Drug: CPX-POM - 120 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-POM
Trial: NCT03348514
Drug: CPX-POM - 240 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-POM
Trial: NCT03348514
Drug: CPX-POM - 360 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-POM
Trial: NCT02580058
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
Trial: NCT02293681
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
Trial: NCT02803216
Drug: standard triple region
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
Trial: NCT01906840
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02120417
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
Trial: NCT02120417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg matching placebo tablets to be administered by mouth
Trial: NCT02278978
Drug: BIBF1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF1120 200 mg two times per day orally
Trial: NCT00548912
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03069638
Drug: Sedatives/Hypnotics,Other
RxNorm normalized name: SEDATIVES/HYPNOTICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
Trial: NCT00319163
Drug: levonorgestrel/ethinyl estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00479466
Drug: MK0893
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Trial: NCT00479466
Drug: Placebo to MK0893
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.
Trial: NCT02534337
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Trial: NCT03803215
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
Trial: NCT01373554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mig/bid or 60mg/bid P.O
Trial: NCT00327444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
Trial: NCT02047552
Drug: IV iron placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL normal saline
Trial: NCT01820910
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
Trial: NCT04312997
Drug: PUL-042 Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
Trial: NCT04312997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline for inhalation
Trial: NCT01634243
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Trial: NCT03119649
Drug: GLPG2222 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet(s) containing GLPG2222
Trial: NCT03119649
Drug: GLPG2222 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet(s) containing GLPG2222
Trial: NCT03119649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral tablet(s) containing placebo
Trial: NCT03119649
Drug: GLPG2222 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet(s) containing GLPG2222
Trial: NCT03119649
Drug: GLPG2222 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet(s) containing GLPG2222
Trial: NCT03469310
Drug: Acetaminophen 500Mg Cap
RxNorm normalized name: ACETAMINOPHEN 500MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-narcotic medication first with narcotic as second choice
Trial: NCT03469310
Drug: Tylenol #3 Oral Tablet
RxNorm normalized name: Tylenol #3 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic medication first
Trial: NCT00276289
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03121690
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml saline / day for 7 days
Trial: NCT01586091
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02471963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01199341
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg per oral, twice daily for 14 days
Trial: NCT01199341
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 100 mg per oral, twice daily for 14 days
Trial: NCT00735332
Drug: TLN-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
Trial: NCT02001012
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02287246
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mL
Trial: NCT00770861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets, oral administration
Trial: NCT00662155
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02621333
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
Trial: NCT04278573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml injection of sterilized sesame oil with no active study ingredient
Trial: NCT04011150
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Trial: NCT03466268
Drug: Gumarontinib Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
Trial: NCT01524289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral tablet once daily for 52 weeks
Trial: NCT03331211
Drug: TKIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib combined with Chematherapy
Trial: NCT02985801
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Capsule
Trial: NCT02981212
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination with Mycophenolate Mofetil
Trial: NCT02981212
Drug: ARB
RxNorm normalized name: Arbli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
Trial: NCT00608465
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg x 1 week followed by 10 mg x 9 weeks.
Trial: NCT00267254
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02782481
Drug: ND0612
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02782481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00377962
Drug: Mycophenolic acid (MPA)/azathioprine (AZA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
Trial: NCT00377962
Drug: Calcineurin inhibitors (CNI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
Trial: NCT00377962
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
Trial: NCT00374556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg placebo capsule, once daily at bedtime
Trial: NCT03269591
Drug: diclofenac tablets
RxNorm normalized name: diclofenac Oral Tablet
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drugs
Trial: NCT03653429
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered prior to surgical incision
Trial: NCT00403546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
Trial: NCT00723658
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01939366
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be matched to pregabalin and cebranopadol.
Trial: NCT02551172
Drug: HCP1105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin + Omega-3-acids ethyl esters
Trial: NCT02551172
Drug: HGP0816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin
Trial: NCT02551172
Drug: Placebo of HCP1105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean Oil
Trial: NCT02551172
Drug: Placebo of HGP0816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusion of Rosuvastatin in HGP0816
Trial: NCT01154101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Trial: NCT00432198
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01613092
Drug: Incremental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
Trial: NCT01655407
Drug: Autologous Engineered Skin Substitute
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.
Trial: NCT04691726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus i.v. + continuous i.v. infusion
Trial: NCT04075643
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-385 Tab. 1 Tab., single oral administration under fasting condition
Trial: NCT04269551
Drug: BIVV020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection Route of administration: intravenous
Trial: NCT01802944
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00917384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
Trial: NCT00087620
Drug: XELODA [capecitabine]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01651923
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
Trial: NCT00358163
Drug: PTK787/ZK 222584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken in tablet form daily
Trial: NCT00756002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
Trial: NCT01879020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (TA-8995 1mg)
Trial: NCT01879020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (TA-8995 2.5mg)
Trial: NCT01879020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (TA-8995 5mg)
Trial: NCT01879020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (TA-8995 10mg)
Trial: NCT01879020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (TA-8995 25mg)
Trial: NCT03038022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00635102
Drug: D-Cycloserine PO and Glycine IV
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
Trial: NCT00635102
Drug: Placebo D-Cycloserine PO and placebo Glycine IV
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00635102
Drug: Placebo D-Cycloserine PO and Glycine IV
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00635102
Drug: D-Cycloserine PO and placebo Glycine IV
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02105558
Drug: Combined spinal and epidural anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
Trial: NCT00651040
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
Trial: NCT00631319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04562337
Drug: SHR1316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-L1 antibody
Trial: NCT02162979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01720251
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections of placebo on days 1, 7, 14, 28 and 56
Trial: NCT01720251
Drug: AllerT full dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
Trial: NCT01043640
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
Trial: NCT01043640
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
Trial: NCT01912118
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
Trial: NCT03592862
Drug: HTL0018318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT03592862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT00881205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
Trial: NCT00608140
Drug: Optimal medical therapy (OMT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
Trial: NCT02389881
Drug: TAK-058 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-058 placebo-matching solution
Trial: NCT04231981
Drug: INCMGA0012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
Trial: NCT01329757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a subcutaneously injected daily dose of placebo for 1 year
Trial: NCT02521246
Drug: Candesartan + Chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02521246
Drug: Losartan+hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676309
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
Trial: NCT02167061
Drug: DA-1229_01 fed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00637728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension, 5 mL once daily
Trial: NCT00509106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Trial: NCT00251069
Drug: Glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00893607
Drug: NRL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg NRL001 was administered as a slow release suppository
Trial: NCT00183560
Drug: Antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants continue on dosage of the antidepressant that was used to achieve clinical remission.